Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV

Trial Profile

Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Ranpirnase (Primary)
  • Indications Genital warts
  • Focus Therapeutic Use
  • Sponsors Tamir Biotechnology
  • Most Recent Events

    • 04 Mar 2017 Results presented at the 2017 American Academy of Dermatology late-breaking research session, according to a Tamir Biotechnology media release.
    • 04 Mar 2017 Results published in a Tamir Biotechnology media release.
    • 04 Mar 2017 Primary endpoint (Size of lesions) has been met, according to a Tamir Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top